Innovation is crucial to KARAHCO AS, not only for the health benefits it provides to patients but also because it's our path toward long-term success. As a patient-centric business, our services and projects share the goal of better and more equitable public health, both at the national and international levels. Our strategy involves becoming a key trade supplier for innovative clinical microbiology testing technology, devices, and kits, where we develop and sell our own lines of products based on the patient needs.
A key priority for us is to ensure that our business does not come at the expense of people, society, or the environment. We at KARAHCO AS are committed to follow the guidelines of good business practice adopted by Innovation Norway (https://www.innovasjonnorge.no/en/start-page/about/sustainability/), where it is clearly stated that companies must not participate in any type of corruption, violation of human rights, bad working conditions, projects with harmful effects for consumers, communities, or the environment. We are also pledged to be accountable to all the decisions and projects that we conduct. Our accountability is extended to include activities done by our partners and distributors, to whom detailed due diligence assessments will be conducted. In addition, KARAHCO AS is committed to adhere to the international guidelines and best practices for doing business and/or research in the health sector in Norway or abroad, especially in humanitarian settings, including the Ethical Principles in Health Care (https://www.epihc.org/principles) and ethical standards during pandemics (https://pandemicethics.org/research-scope-and-context/)